A Florida woman is alleging that taking the Type 2 diabetes drug, Actos (pioglitazone), caused her to develop bladder cancer, according to a lawsuit brought against the maker of the drug, Takeda Pharmaceuticals.
The woman began taking Actos from about June 2006 to January 2010, which is when she started to suffer from bladder cancer, allegedly due to Actos, according to the complaint.
The U.S. Food and Drug Administration (FDA) has warned about the risks of taking Actos. In fact, on June 15, 2011, the agency said that taking Actos for more than one year could significantly increase risks of developing bladder cancer. The drug’s safety label was updated to address this risk. Other research supports the link between Actos and bladder cancer. The British Medical Journal published a study In May 2012 that revealed Actos users were twice as likely to develop bladder cancer after two years. A July 2012 Canadian Medical Association Journal report revealed that patients taking Actos were 22 percent likelier to develop bladder cancer. Some of the symptoms of bladder cancer are:
- Blood in the urine
- Frequent urination
- Feeling pain when urinating
The makers of Actos have been embroiled in a growing number of lawsuits that allege the Type 2 diabetes drug caused them to develop bladder cancer. In the first of some 3,000 Actos injury lawsuits to go to trial, jurors found Takeda Pharmaceutical must pay $6.5 million in damages to a California man who was diagnosed with terminal cancer in 2011 and had taken Actos for more than four years.
This lawsuit was filed by national law firm, Parker Waichman LLP, on behalf of the Florida women, on July 15, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-2244). This case is one of thousands of cases filed as part of the multidistrict litigation (MDL) entitled In Re: Actos (pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as defendants. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation.